Cota, a New York-based oncology real-world data and analytics company, receives an investment from Deerfield Management, and existing investors.
The amount of the deal was not disclosed.
The company intends to use the funds to further expand RWD platform & services to drive more efficient and inclusive drug development.
Led by CEO Miruna Sasu, Cota offers a patient-first approach to cancer care that uses real-world data. The company leverages technology-supported human data abstraction methods to make sense of complex, fragmented patient data from the real world. Cota is also announcing the expansion of its data platform to cover nearly 2 million cancer patient lives throughout the U.S. — quadrupling data access in just two years and now including emerging types of data such as full genomic data.
The company is also launching new services aimed at supporting life sciences companies with drug submissions to the Food and Drug Association (FDA) and European Medicines Agency (EMA). These new services include integrating real-world data in research and development, enabling health economics and outcomes research (HEOR), and informing market-access strategies.
Cota is also now integrating emerging types of data in their platform, including clinicogenomics, social determinants of health, and sexual orientation and gender identity (SOGI). The company also recently launched their Vantage product, which gives subscribers real-time access to broad, curated datasets that are proactively refreshed with new data elements and records.
FinSMEs
26/10/2022